Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 110

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 110
---
 in Common Stock issued for cash                             |     |            |          |   |     |            |  212,297 |   |
| Net                                                                     
 Cash Provided by (Used in) Financing Activities                         |     |            |   65,799 |   |     |            |  165,797 |   |
| Net                                                                     
 Increase (Decrease) in Cash                                             |     |            |     (581 | ) |     |            |    3,460 |   |
| Cash                                                                    
 at Beginning of Period                                                  |     |            |      716 |   |     |            |  121,037 |   |
| Cash                                                                    
 at End of Period                                                        |     | $          |      135 |   |     | $          |  124,497 |   |
| Supplemental                                                            
 Disclosure of Noncash investing and financing activities:               |     |            |          |   |     |            |          |   |
| Preferred                                                               
 Shares Issued for Debt                                                  |     |            |          |   |     |            |          |   |
| Cash                                                                    
 Paid for Interest                                                       |     |            |          |   |     |            |          |   |
| Common                                                                  
 shares Issued for Interest                                              |     |            |          |   |     |            |          |   |
| Preferred                                                               
 Shares issued for Interest                                              |     |            |          |   |     |            |          |   |

<div align='center'>The Accompanying Notes are an Integral Part of These Financial Statements

87

REGEN BIOPHARMA, INC.

Notes to Condensed Consolidated Financial Statements

As of December 31, 2024</div>

These Notes have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company was organized April 24, 2012 under the laws of the State of Nevada

The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials.

The Company is currently engaged in actively identifying small molecules that inhibit or express NR2F